STELARA
Stelara (ustekinumab) is a human interleukin-12 and -23 antagonist indicated for the treatment of several chronic inflammatory conditions. It is approved for use in adult patients with moderate to severe plaque psoriasis, active psoriatic arthritis, and moderately to severely active Crohn's disease or ulcerative colitis. Additionally, the medication is indicated for pediatric patients aged 6 years and older with moderate to severe plaque psoriasis or active psoriatic arthritis. For patients with plaque psoriasis, it is specifically intended for those who are candidates for phototherapy or systemic therapy.
How STELARA Works
Ustekinumab is a monoclonal antibody that binds specifically to the p40 protein subunit shared by the IL-12 and IL-23 cytokines. By targeting this subunit, the drug prevents these cytokines from interacting with the IL-12Rβ1 cell-surface receptor. This disruption inhibits the signaling and cytokine cascades involved in inflammatory and immune responses, such as natural killer cell activation and T-cell differentiation.
Details
- Status
- Prescription
- First Approved
- 2009-09-25
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
STELARA Approval History
What STELARA Treats
4 indicationsSTELARA is approved for 4 conditions since its original approval in 2009. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Plaque Psoriasis
- Psoriatic Arthritis
- Crohn Disease
- Ulcerative Colitis
STELARA Target & Pathway
ProTarget
A cytokine that promotes Th17 cell development and maintenance. IL-23 is upstream of IL-17 in the inflammatory cascade driving psoriasis and inflammatory bowel disease. Blocking IL-23 provides sustained control of these conditions.
STELARA Competitors
Pro6 other drugs also target IL-12. Compare mechanisms, indications, and trial activity.
Competitors share the same molecular target (IL-12). Earlier expiry dates signal biosimilar/generic opportunities.
Drugs Similar to STELARA
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
STELARA FDA Label Details
ProIndications & Usage
FDA Label (PDF)STELARA is a human interleukin-12 and -23 antagonist indicated for the treatment of: Adult patients with: moderate to severe plaque psoriasis (PsO) who are candidates for phototherapy or systemic therapy. active psoriatic arthritis (PsA) . moderately to severely active Crohn's disease (CD) . moderately to severely active ulcerative colitis. Pediatric patients 6 years and older with: moderate to severe plaque psoriasis (PsO) , who are candidates for phototherapy or systemic therapy. active psoriatic arthritis (PsA) . 1.1 Plaque Psoriasis (PsO) STELARA is indicated for the treatment of adults an...
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.